Maynard Um
-
-
-
-
-
-
-
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
-
-
-
-
-
-
-
Ensysce Biosciences (ENSC) files for 20.34M share offering by selling stockholders
-
-
-
-
-
-
-
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
-
-
-
-
-
-
-
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
-
-
-
-
-
-
-
Ensysce Biosciences receives FDA approval for PF614 manufacturing approach
-
-
-
-
-
-
-
Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025
-
-
-
-
-
-
-
Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
-
435,845 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

